A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
This early-stage study is testing a new medication called ZE46-0134 for adults with acute myeloid leukemia, a type of blood and bone marrow cancer. Researchers want to see if this new treatment is safe and how well it works for patients whose cancer has returned or has not responded to other treatments.
You may be able to join if you are 18 or older, have acute myeloid leukemia that has returned or resisted treatment, and have specific gene mutations known as FLT3 or spliceosome mutations. There are also specific rules about prior treatments, such as whether you have taken a drug called Gilteritinib.
During the study, you will receive the investigational medication ZE46-0134 while doctors carefully monitor your health and safety. The study team will check how your body processes the drug and look for early signs that it is helping fight your cancer.
This study is currently recruiting participants at medical centers in Los Angeles, San Francisco, and Atlanta. Your care team can help you figure out if traveling to one of these locations is right for you.
- 1Testing a new medication called ZE46-0134 for specific types of blood cancer.
- 2Open to adults with leukemia that has come back or not responded to previous therapies.
- 3Currently looking for participants at centers in California and Georgia.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.